Tom Wilbur is Director of Public Affairs at PhRMA focusing on federal advocacy priorities including Medicare and intellectual property. Prior to joining PhRMA, Tom worked in politics and on Capitol Hill, most recently responsible for communications and strategy for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom is a proud Michigander and outside of the office enjoys reading, running, hiking, golfing, live music, and spending time with family and friends.
Recent Posts
Deep dive: The issues that drove the 2020 vote
By Tom Wilbur | November 13, 2020
The 2020 election provided much-needed clarity on the issues that matter most to Americans. Here are three key takeaways:
Read More
New video: See how strong IP protections lead to stronger treatments for patients
By Tom Wilbur | November 9, 2020
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP...
Read More
Voters want to address the real drivers of health care costs for patients and the system
By Tom Wilbur | November 2, 2020
COVID-19 has understandably reshaped the health care conversation surrounding the upcoming election, with roughly one-fifth of voters citing the coronavirus pandemic as the priority issue heading...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | October 28, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
How does Medicare Part D impact you?
By Tom Wilbur | October 21, 2020
Whether you are a direct beneficiary, a caregiver or simply an American taxpayer, Medicare Part D impacts you. The Medicare Part D program, which was created by the Medicare Modernization Act...
Read More
Open Enrollment: How to find a Medicare plan that meets your needs
By Tom Wilbur | October 14, 2020
Medicare’s annual open enrollment period is right around the corner. In fact, beginning October 15 and running through December 7, newly qualified patients and current Medicare beneficiaries may...
Read More
The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development
By Tom Wilbur | October 7, 2020
America’s biopharmaceutical companies are committed to COVID-19 treatment and vaccine research and development (R&D). Reliable IP protections have helped drive innovation and enhance patient...
Read More
Three reasons why repealing the Part D non-interference clause is a bad idea
By Tom Wilbur | October 1, 2020
For more than a decade, Medicare Part D has provided seniors affordable and comprehensive prescription drug coverage. Its unique, market-based structure has kept overall Part D program costs far...
Read More
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
By Tom Wilbur | September 30, 2020
The rapid spread and impact of COVID-19 has sparked a global race to find effective treatments and preventative vaccines with the U.S. biopharmaceutical industry leading the charge. America’s...
Read More
National Medicare Education Week: The history of Medicare Part D
By Tom Wilbur | September 15, 2020
Today, in honor of National Medicare Education Week, we’ll be taking a quick look back at the history of Medicare, specifically the Medicare Part D prescription drug benefit .
Read More
Medicare Monday (100)
340B Spotlight (45)
Cost & Consequence (0)
